Preclinical Oncology

Affordable Quality, Guaranteed

Life Inspired
 Results Driven
 Service Focused



www.myer-research.com/preclinical-oncology

www.myer-research.com/preclinical-oncology

Life has an intrinsic ability to succeed beyond incalculable odds. Evidence of its resilience is all about. Examples of simple, elegant, even beautiful solutions abound.

We never cease to be inspired by the wisdom encoded within nature. At MYER RESEARCH, we look to life for the answers to better health.

Rey Magaña Chief Executive Officer



About **MYER** RESEARCH

MYER RESEARCH's preclinical oncology services group has over 30 years of experience with design and execution of efficacy studies for cytotoxic, biologics, medical device, and other therapies. We specialize in in vivo xenograft studies and provide supporting services including in vitro assays and veterinary clinical diagnostics.

Why Xenografts?

The Gold Standard in Oncology...

In vivo xenograft efficacy evaluations remain the gold standard and the workhorse of oncology preclinical research.

Xenograft models combine the advantages of working with human cancers with the physiological relevance of an in vivo host.

Typically, immunocompromised mice such as athymic nude, SCID or knockout mice serve as hosts for a wide variety of human tumors effectively serving as proxies for human subjects. A search on PubMed returns over 108,000 published research articles related to xenograft models, providing an unmatched depth of reference information.

Xenograft models remain a mainstay in oncology research, playing a key role in drug discovery and development.

Why **MYER** RESEARCH ?

Our performance is guaranteed:

At **MYER** we understand that resources and time are limited and that ultimately performance is the catalyst of success.

Our **MYER** validated *XenoScreen*[™] models are guaranteed to perform to specification or your money is refunded.

We provide an unmatched value proposition:

At MYER we have upfront pricing, with no hidden fees. Our pricing is inclusive of a GLP-like raw data package, statistical analysis and a final report.

We have the systems to ensure quality:

<u>Validated Models</u> – At **MYER** we validate our models to ensure consistency and positive control performance.

<u>GLP-like compliance</u>- Although GLPx compliance is not a requirement for your preclinical research or IND submissions, at **MYER** we believe that Good Laboratory Practices add value to your research and provides a higher level of confidence. We therefore have implemented a GLP- like operating approach.

AAALAC - At **MYER** we recognize the contribution that research animals make to science and human health and therefore adhere to the PHS's (OLAW) ILAR, Guide for the Care and Use of Laboratory Animals. We anticipate AAALAC accreditation by the summer of 2025. AAALAC stands for the "Association for Assessment and Accreditation of Laboratory Animal Care." More than 1,050 companies, universities, hospitals, government agencies and other research institutions in 50 countries have earned AAALAC accreditation, demonstrating their commitment to responsible animal care and use.

Our Services:

Models:

Traditional xenograft studies involve the transplantation of human tumor lines to nude or SCID mice. Syngeneic studies involve inoculation of species-specific tumor lines to matching rodent strains. Both traditional xenografts and syngeneic models are available. PDX (patient derived xenografts) involve the transplantation of human tissues in their native state rather as dissociated tumor monocultures (tumor cell lines).

In vivo efficacy of test agents can be determined using a variety of dose schedules and routes including:

 Subcutaneous 	 Intravenous 	 Controlled release
 Intraperitoneal 	♦ Oral	

Tumor types:

MYER's library of human tumor cell lines are available for common malignancies including:

 Breast 	Prostate	Pancreas	♦ Hematopoietic
Colon	Ovary	Melanoma	
♦ Lung	Head and Neck	♦ CNS	

Classes of agents:

MYER RESEARCH has experience with many different classes of agents including:

Traditional cytotoxics

- Gene therapies
- Non-traditional anticancer agents
- Drug delivery and targeting systems
- Devices

Study Design:

٠

MYER RESEARCH can follow your custom protocol, design one for you after consultation with your scientists, or use standard NCI protocols.

Pricing and Service Commitment:

MYER RESEARCH is committed to providing on-time delivery and quality service that exceeds expectations. Our validated XenoScreen[™] models are guaranteed to perform to specification or your money is refunded.

Please call to receive the most competitive pricing in the industry. Affordable, quality, guaranteed.



Contact MYER RESEARCH

rey@myer-research.com Tel: (951) 852 4419 Napa, California USA